Pharvaris N.V. (PHVS)

Market Cap	909.49M
Revenue (ttm)	n/a
Net Income (ttm)	-164.88M
Shares Out	54.49M
EPS (ttm)	-3.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,946
Open	15.72
Previous Close	16.56
Day's Range	15.72 - 16.98
52-Week Range	11.51 - 25.50
Beta	-2.85
Analysts	Strong Buy
Price Target	39.20 (+135.44%)
Earnings Date	May 13, 2025

About PHVS

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 108
• Stock Exchange: NASDAQ
• Ticker Symbol: PHVS
• Website: https://pharvaris.com

Financial Performance

Financial numbers in EUR

Analyst Forecast

According to 5 analysts, the average rating for PHVS stock is "Strong Buy." The 12-month stock price forecast is $39.2, which is an increase of 135.44% from the latest price.

Price Target

$39.2

(135.44% upside)

Analyst Consensus: Strong Buy